IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.

In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Howard D. Edington, MD, discussed Allegheny Health Network’s recently unveiled Melanoma and Skin Cancer Center and its new technology.